Manufacturing Facility
The cornerstone of Ghana's vaccine production efforts is the state-of-the-art fill-and-finish vaccine manufacturing facility being built in Accra. This facility, which may be directly related to or part of Seravac, represents a significant investment in Ghana's pharmaceutical infrastructure. Key features of the facility:
Advanced Fill-and-Finish Capabilities
The facility will handle the final stages of vaccine production—filling, sealing, and labeling vaccine vials with precision and high efficiency. It will use advanced technology to ensure quality and contamination-free packaging, meeting high demand and supporting quick responses to health crises.
Focus on Vaccines Prioritized for the African Continent
Ghana’s facility will focus on vaccines for diseases that predominantly affect Africa, such as malaria, tuberculosis, HIV, and regional outbreaks. This will reduce dependence on imports and ensure a steady, reliable supply for African nations, allowing for faster responses to health emergencies.
Designed to Meet International Quality Standards
The facility will adhere to international quality standards, such as WHO’s Good Manufacturing Practices (GMP). This ensures that vaccines are safe, effective, and globally recognized, positioning Ghana’s pharmaceutical industry as reliable and credible on the world stage.
Potential for Expansion to Cover the Full Spectrum of Vaccine Manufacturing
While starting with fill-and-finish, the facility is designed to expand into full vaccine manufacturing, including producing active ingredients and other critical production stages. This would increase self-sufficiency, reduce costs, and position Ghana as a regional vaccine hub.
